It seems more than likely that current FDA chief, Robert Califf, will be replaced when Donald Trump takes over as President later this month. He has served as chief of the agency for less than a year, but what a year it has been. In a recent interview, Califf talks about some of the most controversial and exciting decisions to be made in 2016, including the FDA approval for the Duchenne muscular dystrophy drug, and the passage of the 21st Century Cures Act, as well as some of the most pressing challenges the FDA will face moving forward.

To access this interview, click here.